| Publication | Year | ||||||||
|---|---|---|---|---|---|---|---|---|---|
|
Complement inhibition in ANCA vasculitis Authors : David JayneJournal : Néphrologie & Thérapeutique Journal Reference count : 40 Volume : 15 Pages : 409-412 |
2019 | ||||||||
|
Extending the Indications for Rituximab in ANCA-Associated Vasculitis Authors : David JayneJournal : New England Journal of Medicine Journal Reference count : 12 Volume : 371 Pages : 1839-1840 |
2014 | ||||||||
|
New-generation therapy for ANCA-associated vasculitis Authors : David JayneJournal : Clinical and Experimental Nephrology Journal Reference count : 20 Volume : 17 Pages : 694-696 |
2013 | ||||||||
|
L27. Antibodies versus phenotypes: A clinician's view Authors : David JayneJournal : La Presse Médicale Journal Reference count : 32 Volume : 42 Pages : 579-582 |
2013 | ||||||||
|
Role of Rituximab Therapy in Glomerulonephritis Authors : David JayneJournal : Journal of the American Society of Nephrology Journal Reference count : 32 Volume : 21 Pages : 14-17 |
2010 | ||||||||
|
Review article: Progress of treatment in ANCA‐associated vasculitis Authors : DAVID JAYNEJournal : Nephrology Journal Reference count : 66 Volume : 14 Pages : 42-48 |
2009 | ||||||||
|
Authors :
David Jayne
Journal : Best Practice & Research Clinical Rheumatology Journal Reference count : 24 Volume : 23 Pages : 445-453 |
2009 | ||||||||
|
Predictors of outcome in renal vasculitis Authors : DAVID JAYNEJournal : Nephrology Journal Reference count : 13 Volume : 9 Pages : 254-255 |
2004 | ||||||||
|
Current Attitudes to the Therapy of Vasculitis Authors : David JayneJournal : Kidney and Blood Pressure Research Journal Reference count : 27 Volume : 26 Pages : 231-239 |
2003 | ||||||||
|
Authors :
David Jayne
Journal : Seminars in Respiratory and Critical Care Medicine Volume : 19 Pages : 69-77 |
1998 | ||||||||
|
Current trends in therapy for primary systemic vasculitis Authors : David JAYNEJournal : Nephrology Journal Reference count : 10 Volume : 3 |
1997 | ||||||||